Patients with type 2 diabetes and obesity
Conditions
Interventions
Each subject will be followed for a run-in period of 4 weeks before being chosen at random for daily administration of ether beraprost sodium or a placebo with the same appearance of an alternative dr
Sponsors
Graduate School of Medicine, University of Tokyo Department of Metabolic Diseases
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetes HbA1c<8.4% BMI>25
Exclusion criteria
Exclusion criteria: Patients with bleeding tendency Patients with Type 1 diabetes or secondary diabetes Patients with severe renal dysfunction Patients with liver dysfunction Patients with a past history if drug hypersensitivity Pregnant women or women with breast-feeding Patients who took prostaglandin derivatives within 3 months Patients whose prescription drugs were changed within 3 months All Patients who is unsuitable for this trial at a physician's discretion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effects of beraprost sodium sustained-release tablets and placebo on the insulin resistance by glucose infusion rate on euglycemic hyperinsulinemic clamp | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. HOMA-IR (Homeostasis model assessment-Insulin Resistance) To evaluate the effects on the insulin resistance. 2. Fasting blood glucose, Glycoalbumin, HbA1c To evaluate the effects on the glycemic control. 3.ADMA, %FMD To evaluate the effects on the vascular endotherial function. | — |
Countries
Japan
Contacts
Public ContactMikiko Haraguchi
Graduate School of Medicine, University of Tokyo Department of Metabolic Diseases
Outcome results
None listed